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 During the past decade, NADPH oxidase 
has attracted numerous studies because 
this enzyme is unique, as compared with 
other oxidoreductases, in that its primary 
function is to generate reactive oxygen 
species (ROS) (superoxide anions in this 
case), whereas ROS can be generated by 
many other enzymatic systems only as a 
by-product during the catalysis. The 
NADPH oxidase is a multisubunit enzyme 
complex that was originally identi( ed in 
phagocytic leukocytes. * e backbone of 
this enzyme is the cell membrane-bound 
cytochrome b558, which consists of two 
subunits, Nox2 (also known as gp91phox) 
and p22phox, and two cytosolic regula-
tory subunits, p47phox and p67phox, as 
well as a small G protein, Rac. Similar 
enzyme complexes have also been found 
in nonphagocytic cells, and seven Nox iso-
forms (Nox1 – Nox5, Duox1, and Duox2), 
one p47phox isoform (Noxo1), and one 
p67phox isoform (Noxa1) have been iden-
ti( ed in mammalian cells. 1 Recent studies 
in various nonphagocytic cells have 
resulted in the recognition that this 
enzyme may represent an essential endo-
genous origin of cellular oxidative stress and 
cellular injury. 1 On the other hand, ROS 
generated by NADPH oxidase may also act 
as signaling molecules that can be involved 
in modulating a number of intracellular 
signal transduction pathways (redox sign-
aling). 1 In line with this notion, NADPH 
oxidase indeed has been implicated in two 
apparently opposite cellular e7 ects, cell 
proliferation, and apoptosis (see below). 
 In the kidney, all components of the 
NADPH oxidase complex, including 
p22phox, p47phox, and p67phox as well 
as the Nox isoforms 1, 2, and 4, are 
expressed; and these involve ( broblasts, 
endothelial cells, vascular smooth muscle 
cells, mesangial cells, tubular cells, and 
podocytes. 1,2 * e function of NADPH 
oxidase in regulating physiological and 
pathophysiological processes in the kid-
ney remains largely unknown. Several 
lines of  in vitro experiments have shown 
that NADPH oxidase-derived ROS may 
be an important mediator of apoptosis of 
various renal cells. 3,4  In vivo , studies have 
suggested that angiotensin II (Ang II) is 
an important regulator of NADPH oxi-
dase in the kidney, which activates renal 
NADPH oxidase and induces oxidative 
stress following prolonged treatments. 2 
Liu  et al . 5 (this issue) provide further 
experimental evidence showing that 
upregulation of NADPH oxidase may also 
have a pivotal function  in vivo in mediat-
ing proximal tubular cell apoptosis induced 
by Ang II. Using a transgenic mouse model 
with tubular cell-speci( c overexpression 
of angiotensinogen, these authors demon-
strated that chronic treatment with the 
NADPH oxidase inhibitor apocynin sup-
pressed NADPH oxidase activity, reduced 
tubular apoptosis and tubulointerstitial 
fibrosis, and normalized albuminuria. 
Moreover, they demonstrated that the 
protective e7 ects of apocynin were blood 
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A Janus in determining cell fate 
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 NADPH oxidase-derived reactive oxygen species are implicated in apoptosis 
in certain kidney cells. On the other hand, NADPH oxidase is also involved in 
promoting cell proliferation in the kidney. The two faces of NADPH oxidase in 
these situations prompt us to argue that the role of this enzyme in various 
kidney diseases needs to be addressed in a cell-specific manner.
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pressure independent. * ese data suggest 
that Ang II modulates renal tubular cell 
apoptosis, at least partly, by NADPH 
oxidase-dependent ROS generation 
( Figure 1 ). 
 On the other hand, NADPH oxidase 
does have another face in the kidney — that 
is, promoting cell proliferation. For exam-
ple, inhibition of the NADPH oxidase 
function by diphenyleneiodonium sup-
pressed homocysteine-induced prolifera-
tion in cultured mesangial cells. 6 In a 
genetic mouse model of type 2 diabetes, it 
was shown that treatment with pitavasta-
tin ameliorated mesangial proliferation, 
which was associated with a downregula-
tion of Nox4 expression in the kidney, 
indicating an implication of NADPH oxi-
dase in proliferative diabetic nephropa-
thy. 7 Interestingly, some authors have 
reported that Ang II infusion increased 
markers of both cell proliferation and 
apoptosis in tubular epithelial and inter-
stitial cells  in vivo . 8 It is interesting to note 
that, although the functions of NADPH 
oxidase-derived ROS in mediating renal 
cell proliferation and apoptosis seem par-
adoxical, these actions may eventually 
converge at the functional level, in that 
both processes may be detrimental (for 
example, proliferation of mesangial cells 
and apoptosis of tubular cells or podo-
cytes) to normal kidney functions. 
 Currently, factors that determine 
whether NADPH oxidase-derived ROS 
molecules act as a mediator of prolifera-
tion or as an inducer of apoptosis in kid-
ney cells are unclear, and this may be 
dependent on the balance between the 
amount of ROS generated and the antioxi-
dant enzymes available in the cell that can 
con( ne the ROS within speci( c subcel-
lular compartments. 9 It is proposed that 
the speci( city of ROS-mediated signaling 
requires spatial con( nement of oxidants 
within a single cell, whereas ROS gener-
ated in a di7 used manner will trigger oxi-
dative stress responses and cell injury. 9 
Moreover, whether NADPH oxidase medi-
ates a proliferative or an apoptotic response 
under a speci( ed condition is likely to be 
cell-type speci( c. For instance, although 
NADPH oxidase-mediated apoptosis 
has been observed in cells including 
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late NADPH oxidase function in the kidney. 
Apocynin, as used by Liu  et al ., 5 is indeed a 
nonspeci( c compound, as it has also been 
shown to have signi( cant impact on arachi-
donic acid metabolism, 11 raising a possibil-
ity that its e7 ects on NADPH oxidase  in vivo 
might be indirect. In  in vitro assays, 
apocynin was usually used in the mmol / l 
range, indicating a low eA  cacy. * us, more 
speci( c and eA  cacious pharmacological 
tools are essential for further con( rmation 
of the functions of NADPH oxidase in vari-
ous kidney diseases, and more importantly, 
for the development of novel therapeutic 
strategies to target this enzyme in the kidney. 
Given the two faces of NADPH oxidase in 
regulating both cell proliferation and apop-
tosis, a more diA  cult task will be how to 
address this question in a cell-speci( c man-
ner — that is, whether a treatment that is 
e7 ective in suppressing apoptosis of one cell 
type will concomitantly compromise the 
regenerative capability of the others. In this 
case, understanding the expression pattern 
and speci( c functions of various NADPH 
oxidase isoforms (for example, Nox1 versus 
Nox4) at di7 erent regions in the kidney may 
provide some clues. * erefore, we can expect 
that studies using gene knockout models to 
distinguish the speci( c functions of di7 erent 
Nox isoforms in kidney cells will be fruitful 
in providing further insights into the sig-
nificance of NADPH oxidase in kidney 
physiology and disease. 
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 Increased oxidative stress in the kidney 
has been recognized in di7 erent pathophys-
iological conditions, such as ischemia –
 reperfusion, chronic renal failure, 
hypertension, and diabetic nephropathy, 
and impaired renal functions may have a 
fundamental role in the development of car-
diovascular complications. Although the 
study by Liu  et al. 5 has clear clinical implica-
tions in this context, it has also brought to us 
a big challenge: how to speci( cally manipu-
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 Figure 1  | Diagram showing the differential functions of NADPH oxidase in modulating 
cell proliferation and apoptosis. NADPH oxidase-derived reactive oxygen species (ROS) may 
promote cell proliferation, survival, and / or hypertrophy by inhibiting the actions of protein 
tyrosine phosphatases (PTPs), thereby enhancing the signaling events mediated by receptor 
tyrosine kinases (RTKs); or by increasing the intracellular Ca 2  +   content by modulating ion channel 
functions. On the other hand, NADPH oxidase activation may result in apoptosis by direct 
activation of proapoptotic kinases or ROS-mediated oxidative damage (indicated by  ‘ X ’ ) to DNA, 
lipids, or proteins. ERK, extracellular signal-regulated kinase; JNK, Jun N-terminal kinase. 
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 The Janus effect: 
two faces of aldosterone 
 Andrew S.  Brem 1 
 Inhibition of the nitric oxide pathway by  N    -nitro- L -arginine methyl 
ester ( L -NAME) is well known to produce hypertension and proteinuria, 
but the mechanisms are less straightforward. Prolonged administration 
of mineralocorticoids mimics the pathological findings produced by 
 L -NAME. Ikeda and colleagues provide a clue to the mechanism by 
showing that exposure to  L -NAME increases plasma aldosterone 50-fold, and 
that spironolactone markedly attenuates the renal changes. Thus, chronic 
 L -NAME exposure may turn out to be a model of ineralocorticoid excess. 
 Kidney International (2009)  75, 137 – 139.  doi: 10.1038/ki.2008.567 
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 In this issue of  Kidney International , Ikeda and 
colleagues1 present a series of experiments 
conducted in a previously well-described rat 
model of renal injury. With the use of an 
inhibitor of nitric oxide production,  N    -nitro-
 l -arginine methyl ester ( l -NAME), rats 
develop hypertension with proteinuria and 
evidence of renal ( brosis over a period of 12 
weeks. The authors present evidence that 
aldosterone mediates some of the renal injury 
in this model in addition to angiotensin II, a 
( nding consistent with the literature. 2 – 4 Treat-
ment with  l -NAME results not only in the 
development of hypertension and signs of 
renal fibrosis but in a more than 50-fold 
increase in plasma aldosterone. Blocking 
aldosterone action with spironolactone atten-
uates the pathological ( ndings, largely inde-
pendently of any e7 ect on blood pressure or 
dietary salt intake. * e contribution of Ikeda 
 et al. 1 lies not in producing another hyperten-
sion – renal injury model but in providing new 
clues to the hormones and pathways govern-
ing renal injury and ( brosis. 
 Ikeda and colleagues 1 show more than 
that aldosterone antagonists attenuate 
renal damage brought on by  l -NAME; 
their ( ndings support a physiological and 
probably important connection between 
nitric oxide metabolism and the genera-
tion of aldosterone. Others have previ-
ously suggested that nitric oxide acts to 
suppress aldosterone secretion directly by 
reducing steroidogenesis in zona glo-
merulosa cells and by downregulating 
angiotensin I receptors, both e7 ects inde-
pendent of guanylyl cyclase. 5 – 8 Using 
 l -NAME to block nitric oxide production 
leads to a profound increase in plasma 
aldosterone levels in the model of Ikeda 
 et al. 1 and makes one wonder whether the 
e7 ects observed are as much the result of 
prolonged mineralocorticoid excess as the 
result of nitric oxide inhibition. 
 Aldosterone has always fascinated stu-
dents of renal physiology, and the hor-
mone has an established role as one of the 
guardians of the composition of the body 
K uids, or Claude Bernard ’ s  milieu int é rieur . 
Early experiments using the toad urinary 
bladder and, later, mammalian renal col-
lecting duct cells clearly showed that 
aldosterone induced transepithelial 
sodium reabsorption. 9 * e sodium trans-
port required a speci( c receptor, which, 
when bound to the hormone, translocated 
to the cell nucleus and eventually led to 
the generation of new proteins. Seminal 
studies later followed that described aldos-
terone ’ s role in renal potassium and hydro-
gen ion secretion. Still later, syndromes of 
mineralocorticoid excess appeared in the 
clinical literature and proved the point that 
too much of a good thing could produce 
electrolyte disturbances and hypertension. 
 Early on, investigators described a curi-
ous paradox regarding aldosterone and its 
actions on the kidney. * e e7 ect of aldo-
sterone on sodium transmembrane trans-
port was easy to demonstrate in cell 
membrane preparations such as the toad 
bladder and isolated perfused renal col-
lecting ducts, yet aldosterone ’ s inK uence 
on renal sodium reabsorption in adrenally 
intact animals could not be reliably 
reproduced. 10 However, animals adrena-
lectomized before treatment with physio-
logical doses of aldosterone clearly showed 
the expected sodium reabsorptive response 
to the hormone. * is was the ( rst evidence 
that aldosterone itself was physiologically 
tightly regulated by naturally occurring 
endogenously generated factors likely 
emanating from the adrenal gland. 
 Uete and Venning first described 
candidate adrenal steroids that might 
interfere with the renal antinatriuretic 
actions of mineralocorticoids. 11 Adminis-
tration of cortisol or its 11-dehydro 
meta-bolite cortisone attenuated the anti -
natriuretic response to both deoxycorti-
costerone acetate and aldosterone in the 
adrenalectomized rat model. * is blunting 
e7 ect of cortisol and cortisone was dose 
dependent. Later, Alberti and Sharp 
expanded prior observations and provided 
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